Sagimet posts Q2 2026 net loss of $14.0M; $257.6M cash funds operations through 2028

Sagimet Biosciences Inc.

2026-Q2 EPS reported -$0.57

Q2 2026 net loss $14.0M vs $10.4M in Q2 2025; H1 2026 net loss $24.6M vs $28.6M.
Cash, equivalents and marketable securities $257.6M as of June 30, 2026, expected to fund operations through 2028.
Phase 3 trial of denifanstat in moderate to severe acne on track to initiate in U.S. in H2 2026.
Phase 1 trial of FASN inhibitor TVB-3567 ongoing; Phase 2 planned before end of 2026.
Completed $175.0M equity financing in April 2026; added to Russell 3000 and Russell 2000 indexes in June.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.